Unfortunately, due to the complex secondary structure of the FRA protein, the development of reagents that can detect the protein with reproducible specificity and high sensitivity is required to support the accurate diagnosis of patients with FRA positive cancers. This evidence concerns the gene FOLR1 and cancer.